Peer-reviewed veterinary case report
Treating dog skin infections with ibafloxacin or marbofloxacin
By Horspool, L J I et al.·Published in Journal of veterinary pharmacology and therapeutics·2004·Intervet International BV, Netherlands·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles.
- Species:
- dog
Plain-English summary
A group of dogs with skin infections called pyoderma were treated with either ibafloxacin or marbofloxacin, two antibiotics that work differently in the body. Most of the dogs had infections caused by a type of bacteria called Staphylococcus intermedius. After treatment, about 74% of the dogs on ibafloxacin and 81% on marbofloxacin showed improvement within a week, and around 70% remained better a month later. Both antibiotics were effective, with only a small number of dogs experiencing a relapse after treatment ended.
People also search for: dog skin infection treatment · ibafloxacin for dogs · marbofloxacin side effects in dogs
Abstract
Dogs with superficial or deep pyoderma (n = 228) presented to first opinion veterinarians (n = 20) were treated orally with either ibafloxacin, at a dosage of 15 mg/kg, or marbofloxacin, at a dosage of 2 mg/kg, once daily for 3-16 weeks. On initial presentation, 35% of the cases were classified as having recurrent pyoderma and 40% as having deep pyoderma. Staphylococci (mainly Staphylococcus intermedius) were isolated from over 90% of the cases. The average treatment periods were 41 +/- 26 and 38 +/- 21 days in the ibafloxacin and marbofloxacin groups, respectively. One week after the cessation of treatment, 74 and 81% of dogs (P > 0.05) in the ibafloxacin and marbofloxacin groups, respectively, were classified as having responded to treatment. One month after the cessation of treatment, 70% of the dogs in each group were still classified as cured or improved, and 3 and 11% (P < 0.05) in the ibafloxacin and marbofloxacin groups, respectively, were classified as having relapsed. Despite having different pharmacokinetic profiles, ibafloxacin and marbofloxacin produced similar results when used under field conditions at the recommended dosages.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15189300/